Eisai Co., Ltd. is a Japan-based pharmaceutical company headquartered in Tokyo that discovers, develops, manufactures, and markets small‑molecule and biologic medicines. The company’s core therapeutic areas are oncology and neurology.
Eisai’s portfolio includes anticancer agents such as lenvatinib (Lenvima, co-developed and co-commercialized with Merck & Co., Inc., known as MSD outside the U.S. and Canada) and eribulin (Halaven), as well as neurology products including donepezil (Aricept), perampanel (Fycompa), and lecanemab (Leqembi, developed with Biogen) for Alzheimer’s disease. The company operates R&D and manufacturing sites in Japan, the Americas, Europe, and Asia and supplies medicines in markets worldwide. Eisai is listed on the Tokyo Stock Exchange (ticker: 4523).
None yet. When a new project in the record names Eisai as owner, partner or investor, it shows here.
Phase 3 LITESPARK‑012 tested pembrolizumab+lenvatinib+belzutifan and a pembrolizumab+quavonlimab+lenvatinib regimen; safety profiles consistent with prior studies; full analysis ongoing.
Phase 3 trial shows WELIREG plus LENVIMA improves progression-free survival in advanced RCC, with FDA reviewing new drug applications.
New data shows improved survival rates for bladder and kidney cancer treatments, highlighting advancements in Merck's oncology portfolio at the ASCO GU Symposium.
The LEAP-012 trial showed no overall survival benefit for the treatment, but progression-free survival improved. The study is closed, and further data analysis is ongoing.
The trial showed significant PFS and ORR improvements with WELIREG and LENVIMA in advanced RCC patients post anti-PD-1/L1 therapy, with consistent safety profiles.
KEYTRUDA and LENVIMA improve 5-year survival rates in advanced endometrial carcinoma compared to chemotherapy, with consistent results across patient subgroups.
Merck presents positive data on KEYTRUDA and other investigational medicines for various cancers, highlighting progress in treatment and research at ESMO 2025.
